Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2012. The report details a specific share repurchase transaction executed on August 9, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 600,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,508 pence per share; lowest price paid was 1,489.5 pence per share.
- Treasury Holdings (Settled): 486,507,927 shares (8.89% of total issued share capital).
- Treasury Holdings (Including Unsettled): 487,957,927 shares (9.79% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,985,123,265 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 600,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 9.79% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (4,985,123,265) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (487,957,927 including unsettled) to assess the impact on voting rights.
- Review the price paid (1,489.5 to 1,508 pence) against the prevailing market price on August 9, 2012.